Discovery

This research identifies the genes and proteins responsible for specific diseases and develops drugs that target them. It is the first step in drug discovery and holds the key to success.

Cancer

Identifies specific genetic mutations and proteins involved in cancer cell proliferation. This leads to the development of molecularly targeted drugs that specifically target these mutations. Examples include drugs for lung cancer with EGFR gene mutations and drugs for breast cancer with HER2 protein overexpression.

Congenital Metabolic Disorders

This disease occurs when specific metabolic pathways cease to function due to gene deletions or mutations. Genome analysis identifies the causative genes, and treatment approaches are sought to compensate for their dysfunction.

Rare Disease

For intractable diseases lacking conventional treatments, we comprehensively analyze patients’ genetic information to identify unknown genes and pathways involved in the disease state.

Biomarkers are substances (such as genes, proteins, or metabolites) that serve as objective indicators of a person’s physical condition or the presence of disease. Biomarker discovery research aims to identify indicators useful for early disease detection, predicting treatment efficacy, and assessing prognosis.

Cancer

By measuring specific genetic mutations or protein levels in blood or tissue, it is utilized for early cancer detection and as a companion diagnostic to predict which anticancer drugs will be effective.

Dementia

We identify proteins indicating the progression of dementia (e.g., amyloid beta, tau) and gene expression patterns indicating inflammation within the brain, utilizing them for diagnosis and monitoring treatment efficacy.

Heart Disease

We identify blood proteins and genetic markers that indicate the risk of myocardial infarction and heart failure, aiding in predicting onset and assessing severity.

To ensure the success of clinical trials, we provide gene analysis and omics analysis technologies. This supports the development of more efficient and personalized treatments.

Patient Stratification

Based on genetic information, we identify subgroups of patients who are likely to respond well to a drug. This increases the success rate of clinical trials and enables us to deliver appropriate treatments to more patients.

Drug Efficacy

We analyze at the genetic level how administered drugs act within the patient’s body to predict their efficacy.

Side Effect Prediction

We predict the risk of drug side effects based on genetic factors and establish safer treatment methods.

Through collaboration with pharmaceutical companies both domestically and internationally, we provide genetic analysis and omics analysis at various stages of the drug discovery pipeline.

Joint Research

We combine pharmaceutical companies’ compound libraries with genetic analysis technologies to identify and screen new drug targets.

Commissioned Analysis

We specialize in analyzing large-scale genomic and omics data for pharmaceutical companies conducting basic and clinical research.

Drug Discovery Project Support

During the development stage of new compounds, we provide guidance to elucidate their mechanisms of action at the genetic level and refine them into more effective drugs.